Abstract
Recent studies show that several Siglec receptors, such as Siglec-8 and Siglec-14, may be important therapeutic targets in asthma and COPD. Siglecs are a family of lectins belonging to the immunoglobulin superfamily and recognize sialic acid residues of glycoproteins. Most of Siglecs have intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIM), implicating them in the suppression of immunoreceptor signaling. Siglec-5/14 may be involved in the negative regulation of innate immune responses. The aim of this study was to analyze Siglec-5/14 expression in induced sputum cells of COPD patients in the following treatment combinations: (1) a long-acting beta2-agonist, formoterol; (2) formoterol combined with a long-acting antimuscarinic agent, tiotropium; and (3) formoterol combined with an inhaled corticosteroid or formoterol combined with tiotropium and with an inhaled corticosteroid. Siglec expression was assessed in sputum cells by flow cytometry using a specific monoclonal antibody. Double staining of cells indicated that Siglec-5/14 is expressed in monocyte/macrophages and neutrophils, but not in lymphocytes. Siglec-5/14 expression was significantly higher in patients receiving combined therapy including inhaled corticosteroids compared with patients taking only formoterol or formoterol + tiotropium. Our results suggest that inhaled corticosteroids may exert beneficial or negative effects, depending on the patients’ phenotype, through increased immunosuppressive Siglec-5 or immunoactivatory Siglec-14 receptors, respectively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Angata T, Hayakawa T, Yamanaka M, Varki A, Nakamura M (2006) Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates. FASEB J 20:1964–1973
Angata T, Ishii T, Motegi T, Oka R, Taylor RE, Soto PC, Chang YC, Secundino I, Gao CX, Ohtsubo K, Kitazume S, Bizet V, Varki A, Gemma A, Kida K, Taniguchi N (2013) Loss of Siglec-14 reduces the risk of chronic obstructive pulmonary disease exacerbation. Cell Mol Life Sci 70:3199–3210
Barnes P (2004) Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 56:515–548
Birrel MA, Wong S, Hele DJ, McCluskie K, Hardaker E, Belvisi MG (2005) Steroid-resistant inflammation in a rat model of chronic obstructive pulmonary disease is associated with a lack of nuclear factor-κB pathway activation. Am J Respir Crit Care Med 172:74–84
Crocker PR, Paulson JC, Varki A (2007) Siglecs and their role in the immune system. Nat Rev Immunol 7:255–266
Ilmarinen P, Kankaanranta H (2014) Eosinophil apoptosis as a therapeutic target in allergic asthma. Basic Clin Pharmacol Toxicol 144:109–117
Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS (2012) Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther 135:327–336
Mroz RM, Holownia A, Wielgat P, Sitko A, Skopinski T, Chyczewska E, Braszko JJ (2013) Siglec-8 in induced sputum of COPD patients. Adv Exp Med Biol 788:19–23
Price D, Yawn B, Brusselle G, Rossi A (2012) Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care Respir J 22:92–100
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176:532–555
Tsoumakidou M, Tzanakis N, Siafakas NM (2003) Induced sputum in the investigation of airway inflammation of COPD. Respir Med 97:863–871
Varki A, Crocker PR (2009) I-type lectins. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME (eds) Essentials of glycobiology. Cold Spring Harbour, New York
Varki A, Gagneux P (2012) Multifarious role of sialic acids in immunity. Ann N Y Acad Sci 1253:16–36
Wielgat P, Holownia A, Braszko JJ (2012) Lipopolysaccharides changes sialylation state in the mouse central nervous system. J Physiol Pharmacol 63:555–561
Yamanaka M, Kato Y, Angata T, Narimatsu H (2009) Deletion polymorphism of Siglec14 and its functional implications. Glycobiology 19:841–846
Yasukawa Z, Sato C, Kitajima K (2005) Inflammation – dependent changes in α2,3-, α2,6-and α2,8-sialic acid glycotopes on serum glycoproteins in mice. Glycobiology 15:827–837
Conflicts of Interest
The authors have no conflicts of interest to be declared in relation to this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Wielgat, P. et al. (2014). Inhaled Corticosteroids Increase Siglec-5/14 Expression in Sputum Cells of COPD Patients. In: Pokorski, M. (eds) Inflammatory Disorders. Advances in Experimental Medicine and Biology(), vol 839. Springer, Cham. https://doi.org/10.1007/5584_2014_51
Download citation
DOI: https://doi.org/10.1007/5584_2014_51
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10011-1
Online ISBN: 978-3-319-10012-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)